[Objective and subjective screens for determining the effectiveness of allogenic bone marrow transplantation in hematologic diseases].
49 cases were reviewed with respect to the risk factors determining the outcome of alloBMT. The presence of HLA/MLC matched sibling or alternatively genetically haploidentical but phenotypically matched family or unrelated donor makes the transplantation possible. In the latter situation matching at the level of genomic DNA is advisable. Among prognostic factors stage of the disease and age of recipients play a significant role. More aggressive conditioning regime is associated with a risk of severe GvHD. A role of microbial status in promoting GvHD was discussed. An overall long term cumulative was 45% being higher in children (65%) and in patients in early stage of the disease (51%). Acute GvHD causes majority of losses (24%). Mild or moderate GvHD was associated with the highest survival due to a low risk of both transplant-related mortality and relapse. Unfortunately, a high proportion of patients were infected with hepatitis B or C virus.
Lange
A
A
Zespół Prezeszczepiania Szpiku Kostnego Oddział Immunoterapii i Prezeszczepiania Szpiku Szpitala im. K. Dłuskiego Instytut Immunologii i Terapii Doświadczalnej PAN.
D000328:Adult; D000367:Age Factors; D016026:Bone Marrow Transplantation / Q000379:methods*; D002648:Child; D006086:Graft vs Host Disease / Q000401:mortality; D006402:Hematologic Diseases / Q000401:mortality / Q000628:therapy*; D006801:Humans; D010641:Phenotype; D012307:Risk Factors; D015996:Survival Rate; D014019:Tissue Donors; D014184:Transplantation, Homologous; D016896:Treatment Outcome
Obiektywne i subiektywne prezesłanki określajace efektywność allogenicznego prezeszczepu szpiku w chorobach krwi.